Results 131 to 140 of about 182,063 (264)

Interstitial lung diseases in the 2020s

La Presse Médicale, 2020
Dominique, Valeyre, Marc, Humbert
openaire   +3 more sources

Serum KL-6 Levels at Acute Exacerbation in Patients With Interstitial Lung Disease. [PDF]

In Vivo
Uchiyama M, Miyazaki K, Maezawa Y, Kayauchi N, Okauchi S, Satoh H, Hasegawa R.   +6 more
europepmc   +1 more source

Integrated Clinical and Proteomic Profiling of CD19 Chimeric Antigen Receptor T Cell Therapy in Progressive Systemic Sclerosis

Arthritis &Rheumatology, EarlyView.
Objective To characterize the clinical, immunologic, and proteomic changes associated with CD19 chimeric antigen receptor T cell therapy in patients with progressive systemic sclerosis (SSc). Methods Patients with progressive SSc received CD19 chimeric antigen receptor (CAR)‐T cell therapy and were observed longitudinally for safety, clinical efficacy,
Chenhan Jia, Wanyi Lin, Zhangyi Zhao, Fenglin Wu, Chaoyu Gu, Yuankai Sun, Zhe Ding, Chang Wei, Xinyu Li, Cuiwei Xie, Peng Xia, Zhen Xia, Xuesong Liu, Shaoying Yang, Chunyan Zhang, Hanlin Yin, Liangjing Lu   +16 more
wiley   +1 more source

Impact of Severe COVID-19 on Interstitial Lung Disease in Autoimmune Systemic Diseases. [PDF]

Respirol Case Rep
Ferri C, de Pinto M, Murdaca G, De Luca G, Beigi DMR, Caira V, Foti R, Cito A, Naclerio C, Luppino JME, Spinella A, Orlandi M, Batani V, Lumetti F, Prampolini F, Varcasia G, Foti R, Riccieri V, Iannone F, Antonelli A, Giuggioli D, COVID‐19 and Autoimmune Systemic Diseases Italian Study Group.   +21 more
europepmc   +1 more source

Human Fibroblast–Myeloid Cell Tissue Atlas Across the Lungs, Synovium, Skin, and Heart

Arthritis &Rheumatology, EarlyView.
Objective The availability of single‐cell RNA sequencing (scRNAseq) data in different tissues and disease states provides an opportunity to compare cellular subsets and identify common and unique cellular activation. In this study, we aimed to characterize shared and tissue‐specific myeloid and stromal phenotypes and to uncover key cellular subtypes ...
Lucy MacDonald, Katerina Apostolopoulou, Olympia Hardy, Melpomeni Toitou, Gabriela Kania, Przemyslaw Blyszczuk, Raphael Micheroli, Thomas D. Otto, Mariola Kurowska‐Stolarska, Caroline Ospelt   +9 more
wiley   +1 more source

Comparative Transcriptional Profiling of Key Macrophage and Fibroblast Subpopulations in Rheumatoid Arthritis–Associated Lung Disease

Arthritis &Rheumatology, EarlyView.
Objective Rheumatoid arthritis (RA) often involves extra‐articular complications, including interstitial lung disease (ILD) and/or pulmonary nodules. Transcriptomic profiling of lung tissue provides the opportunity to directly assess cell‐specific gene expression and corresponding pathway activation in different types of rheumatoid lung disease ...
Tracy Tabib, Ogechukwu Ezenwa, Joshua Sciurba, Eleanor B. Valenzi, John Sembrat, Brittany Cody, Jishnu Das, Robert Lafyatis, Dana P. Ascherman   +8 more
wiley   +1 more source

From Interferon Signature to the Clinical Landscape: Type I Interferonopathies

Arthritis &Rheumatology, EarlyView.
Objective TypeI interferonopathies are heterogeneous diseases driven by dysregulated type I interferon (IFN‐I) signaling. Diagnosis is challenging due to clinical/molecular variability and the need for IFN‐I quantification. The aim of this study was to characterize the clinical, immunologic, genetic, molecular profiles of patients with suspected ...
Ismail Yaz, Seza Ozen, Hacer Neslihan Bildik, Canberk Ipsir, Dilara Unal, Saliha Esenboga, Begum Cicek, Mehmet Emin Seker, Fatima Aerts‐Kaya, Seher Sener, Mehmet Orhan Erkan, Hanife Avci, Deniz Cagdas, Ilhan Tezcan   +13 more
wiley   +1 more source

Telomere biology disorders in childhood interstitial lung disease: from genetic diagnosis to bedside suspicion - A commentary on "Telomere biology disorders associated with childhood interstitial lung disease". [PDF]

Clin Exp Pediatr
Lilitwat W.
europepmc   +1 more source

Efficacy and Safety of Nanoencapsulated Sirolimus Plus Pegadricase: Results From the Randomized, Placebo‐Controlled Phase 3 Trials

Arthritis &Rheumatology, EarlyView.
Objective DISSOLVE I and II examined the efficacy and safety of nanoencapsulated sirolimus (NAS) plus pegadricase (NASP) in patients with uncontrolled gout (UG). Methods In these double‐blind, placebo‐controlled Phase 3 trials of NASP, patients were randomized 1:1:1 to infusions of high‐dose (HD) or low‐dose (LD) NAS plus pegadricase (HD NASP, LD NASP,
Herbert S. B. Baraf, Puja P. Khanna, Milan Petronijevic, Mamuka Lortkipanidze, Anand Patel, Kwabena Ayesu, Michael H. Pillinger, Atul Singhal, Joanna Sobierska, Jacquie Christie, Peter Traber, Rehan Azeem, Wesley DeHaan, Hugues Santin‐Janin, Bhavisha Desai, Alan Kivitz   +15 more
wiley   +1 more source

Role of Interleukin 34 in Pulmonary Vascular Remodeling Associated With Fibrosing Interstitial Lung Disease. [PDF]

Pulm Circ
Yokokawa T, Ueda S, Nishiura K, Okochi S, Ogawara R, Kiko T, Miura S, Misaka T, Oikawa M, Masuishi Y, Kakamu T, Tanino Y, Shibata Y, Hashimoto Y, Muto S, Suzuki H, Inoue KI, Ikeda K, Nakazato K, Ishida T, Takeishi Y.   +20 more
europepmc   +1 more source